STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs

With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Indian J Urol
Autors principals: Sharma, Aditya Prakash, Mavuduru, Ravimohan S., Bora, Girdhar Singh, Devana, Sudheer K, Singh, Shrawan K., Mandal, Arup K.
Format: Artigo
Idioma:Inglês
Publicat: Medknow Publications & Media Pvt Ltd 2018
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034411/
https://ncbi.nlm.nih.gov/pubmed/30034127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/iju.IJU_378_17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars